In 2020, brigatinib was granted full FDA approval for treatment of ALK+ NSCLC on the basis of efficacy and safety results from ALTA-1L, a global randomized phase 3 study comparing brigatinib with crizotinib in patients with tyrosine kinase inhibitor (TKI)-naive ALK+ NSCLC.11 This evidence concerns the gene ALK and non-small cell lung carcinoma.